To grow in this rapidly changing business environment, Daiichi Sankyo reinforces strategy development and implementation through a global management structure that includes six functional units and seven business units reporting to the CEO.
*ASCA:In-house term referring to markets outside Japan, the United States and Europe
Global Management Committee
Global Management Committee members develop Group strategy that quickly and effectively addresses market and environmental trends. They also help facilitate our CEO's decision-making.
Our four corporate units — Corporate Strategy, Global Brand Strategy, Business Development & Licensing, and General Affairs — support our CEO in developing comprehensive and consistent corporate strategies and ensuring smooth management of the Daiichi Sankyo Group. Our four corporate units — Corporate Strategy, Global Brand Strategy, Business Development & Licensing, and General Affairs — support our CEO in developing comprehensive and consistent corporate strategies and ensuring smooth management of the Daiichi Sankyo Group.
Our six functional units - R&D (Research & Development), Biologics, Pharmaceutical Technology, Supply Chain, Medical Affairs, and Quality & Safety - help formulate and execute global strategies. Each unit determines areas that should be expanded globally, guides strategic planning and execution, and improves the efficiency of business operations.
Our business units include four corporate entities in the regions where we operate, as well as three business organizations – Sales & Marketing Unit (Japan), Vaccine Business Unit, and ASCA Company.
Sales & Marketing Unit (Japan)
Sales & Marketing Unit (Japan) is committed to maximizing the Group's business performance in Japan. It consolidates functions focused on our Japanese businesses, which include innovative and established pharmaceuticals (Daiichi Sankyo Espha Co., Ltd.).
Vaccine Business Unit
Vaccine Business Unit enhances the investment strategies for vaccine research, production, and business tie-up and development for Kitasato Daiichi Sankyo Vaccine Co., Ltd.
Daiichi Sankyo Healthcare Co., Ltd.
Daiichi Sankyo Healthcare develops, manufactures and sells non-prescription medications in Japan. The company also offers non-medical goods, cosmetics and medical equipment
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc., our U.S. subsidiary, markets medicines for hypertension, pain management, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma.
Luitpold Pharmaceuticals, Inc.
Luitpold Pharmaceuticals develops and markets drugs and medical devices for healthcare professionals, clinics and hospitals across the United States and Canada
Daiichi Sankyo Europe GmbH
Our European subsidiary, Daiichi Sankyo Europe does business in 12 European countries, including Great Britain, Germany, France, Austria, Belgium, Switzerland, Spain, Italy, Holland, Portugal, Turkey and Ireland
ASCA Company was established to successfully develop strategies for regions outside Japan, the United States and Europe, and to promote medium- and long-term growth in these rapidly growing markets